专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2005014032A2 USES OF SECRETAGOGUES 审中-公开
标题翻译： SECRETAGOGUES的用途
公开(公告)号：WO2005014032A2
公开(公告)日：2005-02-17
申请号：PCT/DK2004/000529
申请日：2004-08-06
申请人： GASTROTECH PHARMA A/S , LANGE, Birgitte, Holst , HANSEN, Christian , NILSSON, Henrik
发明人： LANGE, Birgitte, Holst , HANSEN, Christian , NILSSON, Henrik
IPC分类号： A61K38/25
CPC分类号： A61K38/25 , G01N2333/4745 , G01N2333/475 , G01N2333/65
摘要： The present invention relates, in one aspect, to the use of a secretagogue compound for the preparation of a medicament for the prophylaxis or treatment of cancer cachexia in an individual in need of such treatment. In another aspect, the present invention relates to the use of a ghrelin-like compound for the preparation of a medicament for prophylaxis or treatment of cachexia in an individual by administering a subcutaneous dosage of said medicament to the individual. In a further aspect, the present invention relates to the use of a ghrelin-like compound or a pharmaceutically acceptable salt thereof for the preparation of a medicament for stimulation of appetite in an individual by administering a subcutaneous dosage of said medicament to the individual. Furthermore, the present invention relates to a number of new ghrelin-like compounds and uses thereof, as well as to pharmaceutical compositions and medical packaging comprising the new ghrelin-like compounds.
摘要翻译：本发明一方面涉及促分泌素化合物在制备用于预防或治疗需要这种治疗的个体中的癌症恶病质的药物中的用途。另一方面，本发明涉及生长激素释放肽样化合物在制备用于预防或治疗个体恶病质的药物中的用途，其通过向个体施用所述药物的皮下剂量来进行。另一方面，本发明涉及生长激素释放肽样化合物或其药学上可接受的盐在制备用于刺激个体食欲的药物中的用途，其通过向个体施用所述药物的皮下剂量来进行。此外，本发明涉及许多新的生长素释放肽样化合物及其用途，以及包含新型生长素释放肽样化合物的药物组合物和医药包装。

2. 发明申请

WO2005097173A2 USE OF A SECRETAGOGUE FOR THE TREATMENT OF GHRELIN DEFICIENCY 审中-公开
标题翻译：使用秘密治疗GHRELIN缺乏症
公开(公告)号：WO2005097173A2
公开(公告)日：2005-10-20
申请号：PCT/DK2005/000237
申请日：2005-04-07
申请人： GASTROTECH PHARMA A/S , NILSSON, Henrik , LANGE, Birgitte, Holst , POST, Claes , NIELSEN, Tina, Geritz
发明人： NILSSON, Henrik , LANGE, Birgitte, Holst , POST, Claes , NIELSEN, Tina, Geritz
IPC分类号： A61K38/25
CPC分类号： A61K38/25
摘要： The present invention relates to the use of a growth hormone (GH) secretagogue, such as a ghrelin-like compound, for the preparation of a medicament for the prophylaxis or treatment of ghrelin deficiency, and/or undesirable symptoms associated therewith, in an individual at risk of acquiring partial or complete ghrelin deficiency resulting from a medical treatment and/or from a pathological condition. The present invention also relates to use of a secretagogue compound for the preparation of a medicament for the prophylaxis or treatment of one or more of: loss of fat mass, loss of lean body mass, weight loss, cachexia, loss of appetite, immunological dysfunction, malnutrition, disrupted sleep pattern, sleepiness, reduction in intestinal absorption and/or intestinal mobility problems in an individual suffering from, or at risk of suffering from, ghrelin deficiency. Furthermore, the present invention relates to the use of a secretagogue, such as a ghrelin-like compound, for the production of a medicament for preventing weight increase in an individual either: a) being converted from a hyperthyroidic state to euthyroid state, or b) in remission from being converted from a hyperthyroidic state to euthyroid state.
摘要翻译：本发明涉及生长激素（GH）促分泌素如生长素释放肽样化合物在个体中用于预防或治疗生长素释放肽缺乏症和/或与之相关的不良症状的药物的用途有获得由医疗和/或病理状况引起的部分或完全的生长素释放肽缺乏的风险。本发明还涉及促分泌素化合物在制备用于预防或治疗以下中的一种或多种的药物中的用途：脂肪量的损失，瘦体重的减少，体重减轻，恶病质，食欲不振，免疫功能障碍，营养不良，睡眠模式紊乱，困倦，减少肠道吸收和/或肠道运动问题，或者有遭受生长素释放肽缺乏症的个体。此外，本发明涉及促分泌素如生长素释放肽样化合物在制备用于预防个体体重增加的药物中的用途：a）从甲状腺功能亢进状态转变为甲状腺功能状态，或b ）缓解从甲状腺功能亢进状态转变为甲状腺功能状态。

3. 发明申请

WO2007028394A2 USE OF A GLP-1 MOLECULE FOR TREATMENT OF BILIARY DYSKINESIA AND/OR BILIARY PAIN/DISCOMFORT 审中-公开
标题翻译：用于治疗胆汁淤积症和/或胆汁淤积/分泌的GLP-1分子的使用
公开(公告)号：WO2007028394A2
公开(公告)日：2007-03-15
申请号：PCT/DK2006/000496
申请日：2006-09-06
申请人： GASTROTECH PHARMA A/S , NIELSEN, Tina, Geritz , NILSSON, Henrik , HANSEN, Christian , SCHAMBYE, Hans, T.
发明人： NIELSEN, Tina, Geritz , NILSSON, Henrik , HANSEN, Christian , SCHAMBYE, Hans, T.
CPC分类号： A61K38/26 , G01N2333/605 , G01N2500/02 , G01N2800/08
摘要： The present invention relates to molecules, compositions and methods suitable for the treatment or prevention of biliary dyskinesia and/or pain and/or discomfort originating from the biliary tree. The peptide hormone glucagon-like peptide-1 (GLP-1) has both anti-secretory effects and smooth muscle relaxatory properties in the gastrointestinal tract. GLP-1 exists in several forms, where the natural occurring GLP-1 molecules are GLP-1 (1- 37), GLP-1 (7-37), and the amidated versions GLP-1 (1-36)amide, GLP-1 (7- 36)amide. Other molecules capable of binding to and activating the GLP-1 receptor is herein included in the tern GLP-1 molecules. GLP-1 molecules may be naturally occurring or homologues of GLP-1 having one or more amino acid substitutions or modifications. The GLP-1 molecules are used for the manufacture of a medicament for the treatment or prevention of biliary dyskinesia and/or pain and/or discomfort originating from the biliary tree.
摘要翻译：本发明涉及适用于治疗或预防来自胆道树的胆汁运动障碍和/或疼痛和/或不适的分子，组合物和方法。肽激素胰高血糖素样肽-1（GLP-1）在胃肠道中具有抗分泌作用和平滑肌松弛性质。 GLP-1以几种形式存在，其中天然存在的GLP-1分子是GLP-1（1-37），GLP-1（7-37）和酰胺化GLP-1（1-36）酰胺，GLP -1（7-36）酰胺。在GLP-1分子中包括能够结合并激活GLP-1受体的其它分子。 GLP-1分子可以是具有一个或多个氨基酸取代或修饰的GLP-1的天然存在或同源物。 GLP-1分子用于制造用于治疗或预防胆汁运动障碍和/或来自胆道树的疼痛和/或不适的药物。

4. 发明申请

WO2006111169A1 PHARMACEUTICAL PREPARATIONS OF A GLP-1 MOLECULE AND AN ANTI-EMETIC DRUG 审中-公开
标题翻译： GLP-1分子和抗静脉药物的药物制备
公开(公告)号：WO2006111169A1
公开(公告)日：2006-10-26
申请号：PCT/DK2006/000211
申请日：2006-04-21
申请人： GASTROTECH PHARMA A/S , SCHAMBYE, Hans, T. , NILSSON, Henrik , HANSEN, Christian
发明人： SCHAMBYE, Hans, T. , NILSSON, Henrik , HANSEN, Christian
IPC分类号： A61K38/26
CPC分类号： A61K45/06 , A61K38/26 , A61K2300/00
摘要： The present invention relates to a kit of parts comprising a GLP-1 molecule and an anti-emetic drug, said kit of parts being suitable for separate, sequential or/and simultaneous administration to a subject, preferably a human being. Also provided are combinations of GLP-1 or a GLP-1 analog with one or more anti-emetic drugs, as well as uses of the combinations in the manufacture of medicaments.
摘要翻译：本发明涉及包含GLP-1分子和抗呕吐药物的试剂盒，所述试剂盒适用于对受试者，优选人类的单独，连续或/和同时施用。还提供了GLP-1或GLP-1类似物与一种或多种抗呕吐药物的组合，以及组合制备药物的用途。

5. 发明申请

WO2005082385A1 STRONTIUM-CONTAINING COMPOUNDS FOR USE IN THE PREVENTION OR TREATMENT OF NECROTIC BONE CONDITIONS 审中-公开
标题翻译：用于预防或治疗骨质疏松症的含铑化合物
公开(公告)号：WO2005082385A1
公开(公告)日：2005-09-09
申请号：PCT/DK2005/000140
申请日：2005-02-28
申请人： OSTEOLOGIX A/S , HANSEN, Christian , NILSSON, Henrik , CHRISTGAU, Stephan , BONE, Henry, G., III
发明人： HANSEN, Christian , NILSSON, Henrik , CHRISTGAU, Stephan , BONE, Henry, G., III
IPC分类号： A61K33/24
CPC分类号： A61K33/24 , A61K31/28 , A61K31/56 , A61K31/57 , A61K31/663 , A61K45/06 , A61K2300/00
摘要： A method for the treatment and/or prophylaxis of an ostenonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and/or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and/or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).
摘要翻译：用于治疗和/或预防有需要的哺乳动物中的恶性坏死性骨病的方法，例如特发性或继发性骨坏死，无血管性骨坏死，糖皮质激素诱导的骨缺血/骨坏死，Legg-Calve-Perthes疾病和股骨头坏死，所述方法包括向哺乳动物施用有效剂量的含锶化合物（a）。用于治疗和/或预防将要或被治疗的哺乳动物中的骨坏死性骨病，例如特发性或继发性骨坏死，无血管性骨坏死，糖皮质激素诱导的骨缺血/骨坏死和股骨头坏死的方法具有已知或怀疑诱导骨细胞凋亡和/或坏死的治疗剂（b），该方法包括与（b）组合施用含锶化合物（a）。

6. 发明申请

WO2005110457A2 TREATMENT OF EATING DISORDERS AND INDUCTION OF LIPOLYSIS 审中-公开
标题翻译：治疗排卵障碍和感染的诱导
公开(公告)号：WO2005110457A2
公开(公告)日：2005-11-24
申请号：PCT/DK2005/000328
申请日：2005-05-18
申请人： ADITECH PHARMA AB , HANSEN, Christian , NILSSON, Henrik , SCHÖNHARTING, Florian , SCHAMBYE, Hans T.
发明人： HANSEN, Christian , NILSSON, Henrik , SCHÖNHARTING, Florian , SCHAMBYE, Hans T.
IPC分类号： A61K38/17
CPC分类号： C07K14/575 , A61K38/00
摘要： The present invention relates to PYY or functional equivalents thereof for use in pharmaceutical compositions. The pharmaceutical compositions are in particular useful in the treatment of eating disorders, such as disorders characterised by cravings and binges. The invention further discloses the use of said composition for regulation of lipolysis, e.g. stimulation of lipolysis for the treatment of obesity. The invention further relates to methods of treatment using said compositions. Further included is the combination of PYY or functional equivalents thereof with a secondary active ingredient such as an anti-emetic drug.
摘要翻译：本发明涉及用于药物组合物的PYY或其功能等同物。药物组合物特别可用于治疗进食障碍，例如以渴求和叮咬为特征的病症。本发明进一步公开了所述组合物用于调节脂肪分解的用途。刺激脂肪分解治疗肥胖症。本发明还涉及使用所述组合物的治疗方法。还包括PYY或其功能等同物与次级活性成分如抗呕吐药物的组合。

7. 发明申请

WO2005123192A2 A METHOD OF IMPROVING THE MEDICAL TREATMENT OF PAIN 审中-公开
标题翻译：改善疼痛的药物治疗方法
公开(公告)号：WO2005123192A2
公开(公告)日：2005-12-29
申请号：PCT/DK2005/000401
申请日：2005-06-17
申请人： OSTEOLOGIX A/S , CHRISTGAU, Stephan , HANSEN, Christian , NILSSON, Henrik
发明人： CHRISTGAU, Stephan , HANSEN, Christian , NILSSON, Henrik
IPC分类号： A61P29/00
CPC分类号： A61K31/192 , A61K31/415 , A61K33/24 , A61K2300/00
摘要： Methods for improving pain management in a mammal, the methods comprising administering a combination of a strontium-containing compound and a second therapeutically and/or prophylactically active substance selected from the group consisting of analgesic agents, anti-inflammatory agents and palliative agents to the mammal. Pharmaceutical compositions for use in such methods, comprising a strontium-containing compound and a second therapeutically and/or prophylactically active substance selected from the group consisting of analgesic agents, anti-inflammatory agents and palliative agents.
摘要翻译：用于改善哺乳动物疼痛管理的方法，所述方法包括向哺乳动物施用含锶化合物和选自镇痛剂，抗炎药和姑息治疗剂的第二治疗和/或预防活性物质的组合物。用于这种方法的药物组合物，其包含含锶化合物和选自止痛剂，抗炎剂和姑息治疗剂的第二治疗和/或预防活性物质。

8. 发明申请

WO2005110454A2 PROTECTIVE BINDING MEMBERS OF PYY FOR THE TREATMENT OF METABOLIC DISORDERS 审中-公开
标题翻译： PYY保护性结合成分治疗代谢性疾病
公开(公告)号：WO2005110454A2
公开(公告)日：2005-11-24
申请号：PCT/DK2005/000329
申请日：2005-05-18
申请人： ADITECH PHARMA AB , NILSSON, Henrik , HANSEN, Christian
发明人： NILSSON, Henrik , HANSEN, Christian
IPC分类号： A61K38/02
CPC分类号： C07K14/57545 , C07K14/72
摘要： The present invention relates to a binding member of PYY or a functional equivalent thereof for use in pharmaceutical compositions. The pharmaceutical compositions are in particular useful in the treatment of metabolic disorders e.g. obesity, eating disorders, such as disorders characterised by cravings and binges and functional gastrointestinal disorders such as irritable bowel syndrome and functional dyspepsia. The invention further relates to methods of treatment using said compositions. Further included is the combination of a binding member of PYY or a functional equivalent thereof with a secondary active ingredient such as PYY or functional equivalents thereof. The invention further describes the use of a binding member of PYY or a functional equivalent thereof for diagnostic purposes.
摘要翻译：本发明涉及用于药物组合物的PYY的结合成员或其功能等同物。该药物组合物特别适用于治疗代谢紊乱，例如肥胖症，进食障碍，如以渴望和暴食为特征的疾病和功能性胃肠疾病如肠易激综合征和功能性消化不良。本发明还涉及使用所述组合物的治疗方法。还包括PYY的结合成员或其功能等同物与第二活性成分例如PYY或其功能等同物的组合。本发明进一步描述了PYY的结合成员或其功能等价物用于诊断目的的用途。

9. 发明申请

WO2005123193A2 A METHOD OF IMPROVING TREATMENTS IN RHEUMATIC AND ARTHRITIC DISEASES 审中-公开
标题翻译：改善治疗和治疗疾病治疗的方法
公开(公告)号：WO2005123193A2
公开(公告)日：2005-12-29
申请号：PCT/DK2005/000404
申请日：2005-06-17
申请人： OSTEOLOGIX A/S , CHRISTGAU, Stephan , HANSEN, Christian , NILSSON, Henrik
发明人： CHRISTGAU, Stephan , HANSEN, Christian , NILSSON, Henrik
IPC分类号： A61P29/00
CPC分类号： A61K31/519 , A61K31/28 , A61K31/403 , A61K31/573 , A61K31/65 , A61K31/663 , A61K31/7008 , A61K31/737 , A61K33/24 , A61K45/06 , A61K2300/00
摘要： Improved treatments of joint diseases, such as, e.g. osteoarthritis and rheumatoid arthritis, and pain, wherein a strontium-containing compound is administered alone or in combination with one or more second therapeutically and/or prophylactically active substances, selected from the group consisting of bisphosphonates, glucosamine, pallitative agents, analgesic agents, disease modifying anti-rheumatic compounds (DMARDs), selective estrogen receptor modulators (SERMs), aromatase inhibitors, non-steroidal anti-inflammatory agents (NSAIDs), COX-2 inhibitors, COX-3 inhibitors, opioids, inhibitors/antagonists of IL-1, inhibitors/antagonists of TNF-α, inhibitors of matrix metallo-proteinases (MMPs), cathepsin K inhibitors, inhibitors/antagonists of RANK-ligand, statins, glucocorticoids, chondroitin sulphate, NMDA receptor antagonists, inhibitors of interleukin-I converting enzyme, Calcitonin gene related peptide antagonists, glycine antagonists, vanilloid receptor antagonists, inhibitors of inducible nitric oxide synthetase (iNOS), N-acetylcholine receptor agonists, neurokinin antagonists, neuroleptic agents, PAR2 receptor antagonists and anabolic growth factors acting on joint tissue components. Pharmaceutical compositions comprising a strontium-containing compound and a second therapeutically and/or prophylactically active substance as defined above.
摘要翻译：改善关节疾病的治疗，例如，骨关节炎和类风湿性关节炎以及疼痛，其中单独施用含锶化合物或与一种或多种第二治疗和/或预防活性物质一起施用，所述第二治疗和/或预防活性物质选自二膦酸盐，葡糖胺，止痛剂，止痛剂，疾病修饰抗风湿化合物（DMARD），选择性雌激素受体调节剂（SERM），芳香酶抑制剂，非甾体抗炎药（NSAID），COX-2抑制剂，COX-3抑制剂，阿片样物质，IL-1抑制剂/拮抗剂，TNF-α的抑制剂/拮抗剂，基质金属蛋白酶（MMPs）的抑制剂，组织蛋白酶K抑制剂，RANK-配体的抑制剂/拮抗剂，他汀类，糖皮质激素，硫酸软骨素，NMDA受体拮抗剂，白细胞介素-I转化酶抑制剂，降钙素基因相关肽拮抗剂，甘氨酸拮抗剂，香草素受体拮抗剂，诱导型一氧化氮合成酶抑制剂（iNOS），N-乙酰胆碱受体激动剂，神经激肽拮抗剂，精神抑制剂，PAR2受体拮抗剂和作用于关节组织成分的合成代谢生长因子。包含含锶化合物和如上定义的第二治疗和/或预防活性物质的药物组合物。

10. 发明申请

WO2005123130A2 COMBINATION TREATMENT WITH 5-LOX INHIBITORS 审中-公开
标题翻译：包含5-LIPOXYGENASE抑制剂组合的病毒性和神经性疾病的改善治疗
公开(公告)号：WO2005123130A2
公开(公告)日：2005-12-29
申请号：PCT/DK2005/000403
申请日：2005-06-17
申请人： OSTEOLOGIX A/S , CHRISTGAU, Stephan , HANSEN, Christian , NILSSON, Henrik
发明人： CHRISTGAU, Stephan , HANSEN, Christian , NILSSON, Henrik
IPC分类号： A61K45/00
CPC分类号： A61K45/06 , A61K31/519 , A61K31/573 , A61K31/65 , A61K31/663 , A61K31/7008 , A61K31/737 , A61K2300/00
摘要： Combination treatments, wherein a 5-LOX inhibitor are administered together with a bone or cartilage beneficial compound in order to obtain a therapeutically beneficial effect in the treatment and/or prophylaxis of osteoarthritis, rheumatoid arthritis, osteoporosis or pain, and pharmaceutical compositions comprising a combination of a 5-LOX inhibitor and a bone and cartilage beneficial compound.
摘要翻译：组合治疗，其中5-LOX抑制剂与骨或软骨有益化合物一起施用以获得治疗和/或预防骨关节炎，类风湿性关节炎，骨质疏松症或疼痛的治疗有益效果，以及包含组合的药物组合物的5-LOX抑制剂和骨和软骨有益化合物。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式